The 2nd annual World Orphan Drug Congress showcases drug development, new drug discovery and innovations related to rare diseases.

event sponsors

Lysogene at World Orphan Drug Congress 2011

Shire Human Genetic Therapies at World Orphan Drug Congress 2011

AVI BioPharma at World Orphan Drug Congress 2011

Oxon Epidemiology at World Orphan Drug Congress 2011

Centric Health Resources at World Orphan Drug Congress 2011

Clinigen Healthcare Limited at World Orphan Drug Congress 2011

Charles River Discovery & Imaging Services at World Orphan Drug Congress 2011

Santhera Pharmaceutical at World Orphan Drug Congress 2011

QCTR Ltd at World Orphan Drug Congress 2011

PSR Group B.V at World Orphan Drug Congress 2011

* Places are selling out fast! * Over 200 delegates already confirmed ***

Companies already attending include:

AVI BioPharma * Baxter * Celgene Corporation * Charles River Discovery & Imaging Services * Dutch Steering Committee on Orphan Drugs * GlaxoSmithKline * Isis Pharmaceuticals, Inc * Merck Serono S.A. * CHDI Foundation, Inc. * CheckOrphan * Pfizer * Rare Disease UK * Rare Diseases Sweden * Rare Disorders Denmark * Shire Human Genetic Therapies * iroPharma Limited * Orphan Europe * Academic Medical Centre * Actelion Pharmaceuticals Ltd * AKU Society * Alaxia * Alcimed * Alexion Europe SAS * Alexion Pharmaceuticals * Amgen LLC * Amicus Therapeutics * Amsterdam Molecular Therapeutics * Apex Healthcare Consulting Ltd * Ares Life Sciences Ag * Ataxia UK * Ataxia UK/euro-Ataxia * Behcet's Society * Biotech Subsidy * Canadian Organisation for Rare Diseases * CellAct Pharma GmbH * Centre Hospitalier Universitaire Vaudois * Centric Health Resources * Chiesi Farmaceutici S.p.A. * CIBERER * Clinigen * Clinigen Healthcare Limited * CMIC * Coulter Partners * Cytheris SA * Digna Biotech S.L * Dilaforette * Dompe SPA * EBE * Enobia Pharma Inc. * Ergomed * Clinical Research Ltd * EU Commission * Forest Laboratories * Fusion IP * Galderma * Galileo Research srl * Gene Spotlight, Inc. * Genethon * Genetic Alliance * Genzyme * gmp-orphan SAS * Greek Alliance for Rare Diseases (PESPA) * Hemaquest Pharmaceuticals * Huferdis Rare Disease Hungary * Idis Partner for Life * Innolyst * INSERM * Lysogene * Max Neeman Medical International * Medison Pharma * Medivir AB * Medunik Canada * MorphoSys AG * National Specialised Commissioning Team * Neurosearch A/S * Newron * Pharmaceuticals SpA * NIH Centre for Translational Therapeutics * NovImmune * Orphazyme * Otsuka Novel Products GmbH * Oxon Epidemiology * Promethera Biosciences * Proraris * Alliance Maladies * Prosensa * Protalix Biotherapeutics * PSR Group B.V * PTC Therapeutics * QCTR * RaDi Org * Sangart * Sanquin Research Division * Santhera Pharmaceutical * Seaside Therapeutics, Inc * Shire * Shire HGT * Shire Pharmaceuticals Ltd * Skogsmollan * Swedish Orphan Biovitrum * Synthon Bv * TGRD (Europe) * The Planning Shop international * The Wellcome Trust * TheraVida, Inc. * to-BBB Technologies * Uniamo F.I.M.R * United States Army Medical Material Development Activity * University of Leeds * University of Sheffield * Vertex Pharmaceuticals

The World Orphan Drug Congress is the industry-led Orphan Drug conference tackling global trends, market access and collaborations from big pharma, orphan specialists and patient organisations to impact rare diseases.

Register to attend The World Orphan Drug Congress »	See full conference programme »	Download the brochure »
Come to The World Orphan Drug Congress 2011 and discover: The international collaborative initiatives spurring the next generation of rare disease treatments Best practice for achieving reimbursement and market access for your orphan drug How to maximise the commercial potential of an orphan drug through expansion into multiple indications The importance of patient partnerships to ensuring successful orphan drug development New and cutting edge platforms for creating global rare disease patient registries How to successfully translate research into approved rare disease treatments Innovative case studies of clinical trials designed to overcome regulatory challenges of orphan drug approval You’ll come away with great new ideas to do better business. Register for The World Orphan Drug Congress » Download Sponsorship Prospectus »	Hear from an elite speaker faculty including leading executives from: Pfizer GSK Genzyme Prosensa Amicus Therapeutics Protalix Shire HGT Amsterdam Molecular Therapeutics Celgene Alexion Pharmaceuticals PTC Therapeutics Santhera Pharmaceuticals Swedish Orphan Biovitrum Genetic Alliance Genethon Rare Disease UK AKU Society euro-Ataxia Behcet’s Syndrome Society CheckOrphan NIH European Commission See full speaker list » Register for The World Orphan Drug Congress »	The World Orphan Drug Congress 2011 focuses on: Openly debating the value related pricing of orphan drugs Determining a centralised mechanism to facilitate uniform patient access to orphan drugs Best practice to establish successful collaborations between patient groups and industry The need for comprehensive patient registries for all rare diseases Innovative clinical trials and market approval strategy Crucial lessons learnt from organisations long established and those that are entering the orphan drug market If you need to know the latest innovations in these areas you must attend. Register now » Download Sponsorship Prospectus »

Who should attend: Regulatory Affairs / Strategy Public Policy / Governmental Affairs Clinical Research / Development Scientific / Medical Affairs Corporate / Business Development CxO (Executive, Scientific, Operating) Register for The World Orphan Drug Congress » Download the brochure »	Who should sponcor: Regulatory Affairs / Strategy Public Policy / Governmental Affairs Clinical Research / Development Scientific / Medical Affairs Corporate / Business Development CxO (Executive, Scientific, Operating) Download the brochure » Register for The World Orphan Drug Congress »